Therefore, some breast cancer cases carry a triple biomarker signature—the levels of nuclear VDR, CTSL and TP53BP1 that may be exploited in projecting a treatment strategy in TNBC cases. This evidence concerns the gene TP53BP1 and breast carcinoma.